Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Prevention and risk

Topic: Amyloid, tau and blood-test diagnosis

Despite mortality due to communicable diseases, poverty, and human conflicts, dementia incidence is destined to increase in the developing world in tandem with the ageing population. Current data from developing countries suggest that age-adjusted dementia prevalence estimates in 65 year olds are high (>or=5%) in certain Asian and Latin American countries, but consistently low (1-3%) in India and sub-Saharan Africa; Alzheimer's disease accounts for 60% whereas vascular dementia accounts for approximately 30% of the prevalence. Early-onset familial forms of dementia with single-gene defects occur in Latin America, Asia, and Africa. Illiteracy remains a risk factor for dementia. The APOE epsilon4 allele does not influence dementia progression in sub-Saharan Africans. Vascular factors, such as hypertension and type 2 diabetes, are likely to increase the burden of dementia. Use of traditional diets and medicinal plant extracts might aid prevention and treatment. Dementia costs in developing countries are estimated to be US$73 billion yearly, but care demands social protection, which seems scarce in these regions.

Key findings

Why it matters

This 2008 review (not a new study) reports that dementia in people aged 65 was estimated at 5% or more in "certain Asian and Latin American countries" but "consistently low (1-3%) in India and sub-Saharan Africa", with Alzheimer's making up about 60% of cases and vascular dementia about 30%. It names illiteracy, hypertension and type 2 diabetes as factors linked to dementia burden, and says only that traditional diets and plant extracts "might aid" prevention, without testing any. It puts dementia costs in these regions at US$73 billion a year and notes that the social protection care requires "seems scarce".

Study details

How this study scored 57/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 7 of 7; Citations per year 5 of 5; Impact for its field and year 5 of 6; Cited by studies here 4 of 6; Still being cited 3 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multi-centre collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 57 of 100.57 of 100 points earned43 not earned

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (The Lancet. Neurology)
Journal's citation record 3 / 4 The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2008 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 7 / 7 Cited 1,234 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 61.7 citations a year over 20 year(s) since 2008
Impact for its field and year 5 / 6 Cited 32.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 45 other studies in this library
Still being cited 3 / 4 Cited 152 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Piero Antuono: h-index 43 (OpenAlex, whole career)
Institution's track record 2 / 3 University of California San Diego: institution h-index 1,852 (OpenAlex)
Multi-centre collaboration 3 / 3 OpenAlex lists 13 institution(s) in 8 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 18667359)
Free to read 0 / 2 Behind a paywall — scores zero
Total 57 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Kalaria, R. N., Maestre, G. E., Arizaga, R., Friedland, R. P., Galasko, D., Hall, K., et al. (2008). Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(08)70169-8

Vancouver

Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. The Lancet. Neurology. 2008. doi:10.1016/s1474-4422(08)70169-8. PMID: 18667359.

BibTeX

@article{kalaria2008-18667359,
  author  = {Kalaria, R. N. and Maestre, G. E. and Arizaga, R. and Friedland, R. P. and Galasko, D. and Hall, K. and Luchsinger, J. A. and Ogunniyi, A. and others},
  title   = {{Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors}},
  journal = {The Lancet. Neurology},
  year    = {2008},
  doi     = {10.1016/s1474-4422(08)70169-8},
  pmid    = {18667359},
  url     = {https://doi.org/10.1016/s1474-4422(08)70169-8}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 39.

Later studies that cite this one

45 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Prevention and risk

Also tagged “prevalence”

1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →